News

Yann-Alexandre Vano, MD, explains the methods and design of the phase 2 BIONIKK trial for patients with renal cell carcinoma.

Zev A. Wainberg, MD, discusses recent findings from the NAPOLI 3 trial which were presented at the 2023 Gastrointestinal Cancers Symposium.

The phase 3 PhALLCON trial showed a trend toward event-free survival in patients with Philadelphia chromosome positive acute lymphoblastic leukemia when treated with ponatinib compared with imatinib.

Based on the FDA’s review of a new drug application, a phase 2 study will evaluate the safety and efficacy of azeliragon for patients with glioblastoma.

Data from the phase 3 DeFi trial showed that nirogacestat led to a 71% reduction in the risk of disease progression compared with placebo for adult patients with desmoid tumors. Now, the FDA has granted a priority review to the new drug application for nirogacestat.

The developer of avapritinib has announced full registrationL results from the phase 2 PIONEER study of avapritinib for the treatment of indolent systemic mastocytosis.

Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.

Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.

Encouraging results in melanoma have led experts to explore the gut microbiome in colorectal cancer.  The next hot topic in research may be the gut microbiome's role for the prevention, progression, and management of colorectal cancer.

Treatment with (Z)-endoxifen in combination with exemestane plus goserelin in the phase 2 EVANGELINE is now underway.

A phase 1 dose-escalation and -expansion clinical trial will evaluate BA3182, a potential anticancer therapy, for patients with advanced adenocarcinoma based on the clearance of an investigational new drug application from the FDA.

A read out from the phase 3 KEYNOTE-859 at the February ESMO Virtual Plenary hints pembrolizumab/chemotherapy is a new treatment choice for locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

In an interview with Targeted Oncology, Lori Muffly, MD, discusses the subanalysis of a phase 1 study of briquilimab plus low-dose total body radiation and fludarabine which was presented at 2023 Tandem Meetings on Transplantation and Cellular Therapy.

Research shows a high occurrence of ibrutinib-related cardiotoxicity in patients with cancer. This is the first study showing such evidence.

Matthew Ingham, MD, highlights a recent clinical study in the sarcoma space and discusses what else is being evaluated for this patient population.

The FDA has granted a breakthrough therapy designation to mRNA-4157/V940 based on data from KEYNOTE-942 which showed that the addition of an mRNA vaccine to adjuvant pembrolizumab improved recurrence-free survival following resection of high-risk melanoma.

With the main end points of incidence of severe neutropenia and alopecia not met in the phase 1b trial of ALRN-6924 for patients with p53-mutated breast cancer, Aileron Therapeutics has decided to end the trial.

In the phase 3 TORCHLIGHT study, survival advantages were shown with the combination of toripalimab and the chemotherapy agent nab-paclitaxel in patients with recurrent/metastatic triple-negative breast cancer treated in Chinese centers.

Results from cohort A of the MagnetisMM–3 trial of erlanatamab for patients with relapsed/refractory multiple myeloma have led the FDA to grant priority review to a biologics license application for the agent in this patient population.

An analysis with longer follow-up of the ZUMA-3 study showed patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with brexu-cel had a median overall survival of 26 months and a complete response plus CR with incomplete count recovery rate of 71%.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.

Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.

Treatment with an anti-VEGF tyrosine kinase inhibitor appears safe for patients with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.

In an interview with Targeted Oncology, John Strickler, MD, discussed the background and goals of the DeFianCe study in the colorectal cancer space.

Moving on to the dose-expansion study of a phase 1b/2a trial of fostroxacitabine bralpamide plus lenvatinib in hepatocellular carcinoma, investigators will assess the recommended phase 2 dose of 30 mg.

Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.

The secondary analysis of the phase 3 CONDOR study showed that given prior positron emission tomography, piflufolastat F 18 demonstrated changes in intended management, reinforcing the agent's clinical utility.